Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome.
Unresponsive autoimmune haemolytic anaemia (AIHA) may require therapy with second-line drugs. There is no consensus that any one of these agents is more effective than another. Mycophenolate mofetil (MMF) is an immunosuppressive drug proven to be effective in reducing renal allograft rejection as well as being used in autoimmune diseases including systemic lupus erythematosus (SLE). We describe its use in two patients who were treated with MMF for AIHA in the context of underlying SLE and antiphospholipid syndrome (APS). The patients showed a good response to treatment with MMF, suggesting a possible role in the treatment of AIHA.
Alba
P
P
The Lupus Unit, Guy's and St Thomas' Trust, London, UK.
Karim
M Y
MY
Hunt
B J
BJ
D000328:Adult; D000744:Anemia, Hemolytic, Autoimmune / Q000150:complications* / Q000188:drug therapy*; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000188:drug therapy; D018501:Antirheumatic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid